Results 141 to 150 of about 257,826 (338)

Severe relapse after cessation of immunosuppressive therapy in a patient with co‐occurrence of neuromyelitis optica spectrum disorder and Sjögren's syndrome: A case report

open access: yesIbrain, EarlyView.
We report a girl with a diagnosis of “neuromyelitis optica spectrum disorder comorbid Sjogren's syndrome” whose condition showed significant improvement after treatment with corticosteroids and immunosuppressive drugs (prednisolone, hydroxychloroquine, and mycophenolate mofetil).
Man‐Min Zhu   +3 more
wiley   +1 more source

Cyclophosphamide efficacy inmaintenance therapy of nephrotic syndrome in patients withchronic glomerulonephritis

open access: yesТерапевтический архив, 2004
Mm. To study effects of cyclophosphamide (CP) on duration of remission in chronic glomerulonephritis (CGN) with nephrotic syndrome (NS). Material and methods.
V L Duman, L I Shkerina
doaj  

Body mass index as a predictive factor for efficacy of adjuvant taxane‐based chemotherapy in early‐stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Body mass index (BMI) potentially influences outcomes among women with early‐stage breast cancer (EBC). Little is known, however, about relationships between BMI and disease prognosis for different adjuvant taxane‐based chemotherapies. Here, the prognostic effect of BMI on disease recurrence was evaluated among EBC patients treated with ...
José A. García‐Saenz   +18 more
wiley   +1 more source

Blood‐based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Soft tissue sarcoma (STS) is a rare and heterogeneous cancer, comprising approximately 1% of all adult cancers and 7%–15% of all childhood cancers. In the advanced stages, chemotherapy remains the standard‐of‐care, but efficacy is limited, with a response rate of 15%–30%, and responses are often short‐lived, with median progression‐free ...
Brie‐Anne Mannah   +2 more
wiley   +1 more source

Adherance to approved protocol chemotherapy for breast cancer at Songklanagarind Hospital

open access: yesJournal of Health Science and Medical Research (JHSMR), 2002
At Songklanagarind Hospital, a protocol for chemotherapy in breast cancer has been used since 1994. The purpose of this study was to examine "non-medical" factors that may reflect non-acceptance of this protocol.
W Achanond   +7 more
doaj  

Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Circulating tumor cells can offer insights into treatment responses and metastatic recurrence, but current analysis methods are limited. Here, the authors tested a newly developed mass cytometry panel comprising biomarkers such as γH2AX and RAD51 in longitudinally monitored metastatic breast cancer patients.
Kathrin Niedermayer   +17 more
wiley   +1 more source

Tracking cancer‐related fatigue during chemotherapy: Insights from a comparative cohort study of early breast cancer patients

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Cancer‐related fatigue is a multifactorial symptom commonly experienced by breast cancer patients treated with chemotherapy. Here, the authors investigated the temporal associations between cancer‐related fatigue and exercise capacity to better tailor exercise interventions during chemotherapy.
Joris Mallard   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy